Expression of oncogenic K-ras from its endogenous promoter leads to a partial block of erythroid differentiation and hyperactivation of cytokine-dependent signaling pathways.
about
Defective erythroid differentiation in miR-451 mutant mice mediated by 14-3-3zetaMASL1 induces erythroid differentiation in human erythropoietin-dependent CD34+ cells through the Raf/MEK/ERK pathwayBCR-ABL but not JAK2 V617F inhibits erythropoiesis through the Ras signal by inducing p21CIP1/WAF1.STAT3 supports experimental K-RasG12D-induced murine myeloproliferative neoplasms dependent on serine phosphorylation.Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.Leukemogenic Ptpn11 allele causes defective erythropoiesis in mice.Molecular targets for the treatment of juvenile myelomonocytic leukemia.Emerging EPO and EPO receptor regulators and signal transducers.A Synthetic Lethal Interaction between Glutathione Synthesis and Mitochondrial Reactive Oxygen Species Provides a Tumor-Specific Vulnerability Dependent on STAT3.K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors.RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia.Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation.Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesisRole of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development.KRAS(G12V) enhances proliferation and initiates myelomonocytic differentiation in human stem/progenitor cells via intrinsic and extrinsic pathways.
P2860
Q24600228-1A9F051A-EBEE-4500-BB4C-204F66BD24ABQ30009940-1AF5B39D-725F-44CB-898C-FE73FFD9D689Q34181572-13F2C0AD-A31A-4A1A-B3D1-85306B8154ECQ34284326-A2B2F27C-A352-42F4-BE88-F6CDD67FF746Q34667782-72C8B831-6B0E-4E77-8DAA-45DE340BD143Q35308167-344B982E-E1B8-477B-B0D3-B0EAE98A4C2DQ35579349-28CA8695-FAED-42E0-B744-F6BEAFB1D97BQ35692391-C4E22814-D2CB-4B9E-8C03-60AB2CDE2115Q35748498-0789F948-EE11-45F0-B3F5-F7C5329E2B96Q36941105-8270F122-0D8C-4C75-B9B1-A63C00457528Q37081990-64873044-1183-4DB3-BF80-CE2FB755490AQ37086934-9232F16C-6E87-412B-BCBA-36046FC8ABA3Q37176577-273A9587-4E36-406A-B87A-01DC353EF8B8Q37822317-95F6F594-8A09-4090-8194-1B0BB0AD6E96Q39618355-F9596AEB-DEFF-44D1-9E23-C9BB2F5670CB
P2860
Expression of oncogenic K-ras from its endogenous promoter leads to a partial block of erythroid differentiation and hyperactivation of cytokine-dependent signaling pathways.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Expression of oncogenic K-ras ...... -dependent signaling pathways.
@ast
Expression of oncogenic K-ras ...... -dependent signaling pathways.
@en
type
label
Expression of oncogenic K-ras ...... -dependent signaling pathways.
@ast
Expression of oncogenic K-ras ...... -dependent signaling pathways.
@en
prefLabel
Expression of oncogenic K-ras ...... -dependent signaling pathways.
@ast
Expression of oncogenic K-ras ...... -dependent signaling pathways.
@en
P2093
P2860
P50
P1433
P1476
Expression of oncogenic K-ras ...... -dependent signaling pathways.
@en
P2093
Caroline Beard
Jing Zhang
Tyler E Jacks
Yangang Liu
P2860
P304
P356
10.1182/BLOOD-2006-09-047050
P407
P577
2007-02-22T00:00:00Z